Earnings ·
Reports Q3 revenue of $24.2M and declares regular quarterly cash dividend of $0.20 per share
IRMDIradimed Corp
Iradimed reported third-quarter 2026 revenue of $24.2 million, a 14% increase from the prior year period, driven by strong demand for its MRI-compatible IV infusion pumps and monitoring systems. GAAP diluted earnings per share rose to $0.51, up from $0.43 in Q3 2025, while non-GAAP diluted EPS reached $0.55. The company also announced a regular quarterly cash dividend of $0.20 per share, payable on November 27, 2026 to shareholders of record as of November 13, 2026. Management provided full-year revenue guidance of $91.6 million to $93.1 million and updated fourth-quarter expectations. Iradimed is a leader in developing innovative magnetic resonance imaging compatible medical devices.